<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361097</url>
  </required_header>
  <id_info>
    <org_study_id>IF18-00003</org_study_id>
    <nct_id>NCT04361097</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation as a Therapeutic Strategy in the Progression of Chronic Kidney Disease</brief_title>
  <official_title>Fecal Microbiota Transplantation as a Therapeutic Strategy in the Progression of Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      What the investigators want to achieve with the protocol is to identify the impact of
      intestinal microbiota transplantation on the progression of chronic kidney disease.

      Hypothesis: Modification of intestinal microbioma of CKD patients by TMF decrease the
      progression of CKD Methodological design: Experimental, prospective, double-blind. Inclusion
      criteria: Being diagnosed with CKD and creatinine clearance less than 60 mL/minute secondary
      hypertension and/or diabetes and older than 18 years
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      What the investigators want to achieve with the protocol is to identify that impact has
      transplantation intestinal microbiota on the progression of chronic kidney disease

      A.-Hypothesis: Modification of intestinal microbioma of CKD patients by TMF decrease the
      progression of CKD.

      B.-Specific objectives: Evaluate whether decreases TMF markers of inflammation in patients
      with CKD after being treated with TMF, evaluate the behavior in CKD progression markers in
      patients undergoing TMF, evaluate the change in bowel microbioma CKD patients before and
      after undergoing TMF.

      C.-Methodological design: Experimental, prospective, double-blind.

      D.-Type of study: Controlled clinical trial

      E.- Population in study:

        1. -Inclusion criteria: Being diagnosed with CKD and creatinine clearance less than 60
           mL/minute secondary hypertension and/or diabetes, older than 18 years.

        2. - Exclusion Criteria: Malignancies whose last treatment has been less than 5 years, he
           is receiving antibiotics for any reason during the month prior to enrollment, having
           received probiotics in the last 3 months, it has been diagnosed with Clostridium
           difficile infection in the last year, it has been previously subjected to TMF ,
           exacerbations of submitting ERC during the 3 months prior or present at the time of
           enrollment.

        3. -Criteria for elimination: Failure to comply in the structured patient monitoring,
           nondelivery of stool samples at set times, the patient decides to no longer participate
           in the study.

      F.- Desing Description: After being selected and randomized patients who meet the criteria
      for inclusion and exclusion, they are assigned to a group to start treatment TMF (capsules
      intestinal microbiota frozen) or a group receive placebo capsules which shall consist of an
      excipient harmless to the body (capsules frozen saline), both will be developed in the
      service Infectolog√≠a.

      Both groups receive frozen for ingestion orally capsules (comprised of TMF or placebo
      according to the randomization) with a frequency of 15 capsules each 12hrs for 4 doses on
      days 1, 10 and 30 of the study. Each capsule must be ingested over a period no longer than 1
      hour.

      measurements characteristic factors of the progression of kidney disease day 0,10, 30, 60,
      90, 120 and 180 be made consisting of:

        -  Proteins in urine 24 hours

        -  Creatinine clearance 24 hours

        -  CBC

        -  serum creatinine

        -  Urea Nitrogen

        -  Urea

        -  Glucose

        -  Uric acid

        -  IS

        -  venous gases

      Blood samples were taken by puncture of peripheral vein by laboratory personnel to assess
      renal function, urine samples will be collected by the patient at home and transported to the
      laboratory, none of these samples will be used for genetic analysis , only samples of faeces
      they underwent genomic analysis, collection of stool samples will days 0, 5, 10 30, 90 and
      180 (on 10, 30, 90 and 180 with a range of +/- 2 days).

      adverse effects questionnaires on days 1, 5, 30 and 60 is performed and quality of life
      assessment on days 0, 10, 30, 90 and 180.

      Monitoring will face on a weekly basis to register if they have submitted infections, adverse
      effects and whether changes have received treatment. Visits will be made in the epidemiology
      and the Regional Center for Kidney Diseases University Hospital
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 7, 2018</start_date>
  <completion_date type="Actual">April 21, 2020</completion_date>
  <primary_completion_date type="Actual">November 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, double blind, experimental</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Third party makes the aleatorization</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Creatinine Clearance</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour Urine Protein</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocytes</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophils</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urea Nitrogen</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric Acid</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive Protein C</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chlorine</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphorous</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH Venous Gasometry</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CO2 pressure venous</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Bicarbonate</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Base Excess</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate</measure>
    <time_frame>6 months</time_frame>
    <description>Arrest CKD progression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Chronic Kidney Disease Due to Hypertension</condition>
  <condition>Chronic Kidney Disease Due to Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Faecal microbiota transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive frozen capsules to be ingested orally constituted of TMF with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will receive frozen capsules to be ingested orally placebo with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Faecal microbiota transplant</intervention_name>
    <description>Both groups will receive frozen capsules to be ingested orally (constituted of TMF or placebo according to the randomization) with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.</description>
    <arm_group_label>Faecal microbiota transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Both groups will receive frozen capsules to be ingested orally (constituted of TMF or placebo according to the randomization) with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be diagnosed with CKD and creatinine clearance less than 60 ml / minute secondary to
             hypertension and / or diabetes.

          -  Age over 18 years

        Exclusion Criteria:

          -  Malignant neoplasms whose last treatment was less than 5 years

          -  Having received antibiotics for any reason during the month prior to enrollment

          -  Have received probiotics in the last 3 months

          -  Have been diagnosed with Clostridium difficile infection in the last year

          -  Have been previously submitted to TMF

          -  Having presented ERC exacerbations during the 3 months prior or present at the time of
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Camacho-Ortiz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario &quot;Dr. Jose Eleuterio Gonzalez, UANL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Jos√© E. Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Choi HH, Cho YS. Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives. Clin Endosc. 2016 May;49(3):257-65. doi: 10.5946/ce.2015.117. Epub 2016 Mar 9. Review.</citation>
    <PMID>26956193</PMID>
  </reference>
  <reference>
    <citation>Cruz-Mora J, Mart√≠nez-Hern√°ndez NE, Mart√≠n del Campo-L√≥pez F, Viramontes-H√∂rner D, Vizmanos-Lamotte B, Mu√±oz-Valle JF, Garc√≠a-Garc√≠a G, Parra-Rojas I, Castro-Alarc√≥n N. Effects of a symbiotic on gut microbiota in Mexican patients with end-stage renal disease. J Ren Nutr. 2014 Sep;24(5):330-5. doi: 10.1053/j.jrn.2014.05.006. Epub 2014 Jul 22.</citation>
    <PMID>25066654</PMID>
  </reference>
  <reference>
    <citation>Felizardo RJ, Castoldi A, Andrade-Oliveira V, C√¢mara NO. The microbiota and chronic kidney diseases: a double-edged sword. Clin Transl Immunology. 2016 Jun 10;5(6):e86. eCollection 2016 Jun. Review.</citation>
    <PMID>27757226</PMID>
  </reference>
  <reference>
    <citation>Guida B, German√≤ R, Trio R, Russo D, Memoli B, Grumetto L, Barbato F, Cataldi M. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial. Nutr Metab Cardiovasc Dis. 2014 Sep;24(9):1043-9. doi: 10.1016/j.numecd.2014.04.007. Epub 2014 May 2.</citation>
    <PMID>24929795</PMID>
  </reference>
  <reference>
    <citation>Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature. 2016 Jul 7;535(7610):75-84. doi: 10.1038/nature18848. Review.</citation>
    <PMID>27383982</PMID>
  </reference>
  <reference>
    <citation>Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013 Jul 20;382(9888):260-72. doi: 10.1016/S0140-6736(13)60687-X. Epub 2013 May 31. Review. Erratum in: Lancet. 2013 Jul 20;382(9888):208.</citation>
    <PMID>23727169</PMID>
  </reference>
  <reference>
    <citation>Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, Aroniadis O, Barto A, Borody T, Giovanelli A, Gordon S, Gluck M, Hohmann EL, Kao D, Kao JY, McQuillen DP, Mellow M, Rank KM, Rao K, Ray A, Schwartz MA, Singh N, Stollman N, Suskind DL, Vindigni SM, Youngster I, Brandt L. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014 Jul;109(7):1065-71. doi: 10.1038/ajg.2014.133. Epub 2014 Jun 3.</citation>
    <PMID>24890442</PMID>
  </reference>
  <reference>
    <citation>Lin CJ, Wu V, Wu PC, Wu CJ. Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure. PLoS One. 2015 Jul 14;10(7):e0132589. doi: 10.1371/journal.pone.0132589. eCollection 2015. Review.</citation>
    <PMID>26173073</PMID>
  </reference>
  <reference>
    <citation>Marotz CA, Zarrinpar A. Treating Obesity and Metabolic Syndrome with Fecal Microbiota Transplantation. Yale J Biol Med. 2016 Sep 30;89(3):383-388. eCollection 2016 Sep. Review.</citation>
    <PMID>27698622</PMID>
  </reference>
  <reference>
    <citation>Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D. Gut microbiome in chronic kidney disease: challenges and opportunities. Transl Res. 2017 Jan;179:24-37. doi: 10.1016/j.trsl.2016.04.007. Epub 2016 Apr 30. Review.</citation>
    <PMID>27187743</PMID>
  </reference>
  <reference>
    <citation>Ramezani A, Massy ZA, Meijers B, Evenepoel P, Vanholder R, Raj DS. Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. Am J Kidney Dis. 2016 Mar;67(3):483-98. doi: 10.1053/j.ajkd.2015.09.027. Epub 2015 Nov 15. Review.</citation>
    <PMID>26590448</PMID>
  </reference>
  <reference>
    <citation>Ranganathan N, Friedman EA, Tam P, Rao V, Ranganathan P, Dheer R. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Curr Med Res Opin. 2009 Aug;25(8):1919-30. doi: 10.1185/03007990903069249.</citation>
    <PMID>19558344</PMID>
  </reference>
  <reference>
    <citation>Rossi M, Johnson DW, Morrison M, Pascoe E, Coombes JS, Forbes JM, McWhinney BC, Ungerer JP, Dimeski G, Campbell KL. SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): a protocol of placebo-controlled randomised cross-over trial. BMC Nephrol. 2014 Jul 4;15:106. doi: 10.1186/1471-2369-15-106.</citation>
    <PMID>24996842</PMID>
  </reference>
  <reference>
    <citation>Sabatino A, Regolisti G, Brusasco I, Cabassi A, Morabito S, Fiaccadori E. Alterations of intestinal barrier and microbiota in chronic kidney disease. Nephrol Dial Transplant. 2015 Jun;30(6):924-33. doi: 10.1093/ndt/gfu287. Epub 2014 Sep 4. Review.</citation>
    <PMID>25190600</PMID>
  </reference>
  <reference>
    <citation>Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013 Feb;83(2):308-15. doi: 10.1038/ki.2012.345. Epub 2012 Sep 19.</citation>
    <PMID>22992469</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 26, 2020</last_update_submitted>
  <last_update_submitted_qc>April 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>Dr. Adrian Camacho-Ortiz</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>fecal microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT04361097/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

